Natriuretic peptides: Biochemical markers of anthracycline cardiac toxicity?

Oncology Research

Volumn 17, Issue 2, 2008, Pages 51-58

  Urbanova, Dagmar ^a   Urban, L ^b   Danova, K ^b   Simkova, I ^b  

^a Comenius University Medical School ^*  (Slovakia)

^b NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

Author keywords

Anthracyclines; Cardiotoxicity; Natriuretic peptides

Indexed keywords

ANTHRACYCLINE; ATRIAL NATRIURETIC FACTOR; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DAUNORUBICIN; DOXORUBICIN; DOXORUBICINOL; IDARUBICIN; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NATRIURETIC PEPTIDE TYPE D;

ACUTE LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LEUKEMIA; LYMPHOMA; MYOCARDIAL DISEASE; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SARCOMA; SOLID TUMOR; SYSTEMATIC REVIEW; SYSTOLIC DYSFUNCTION;

EID: 44849126207     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504008784523621     Document Type: Review

References (55)

1. Simbre, V. C.; Duffy, S. A.; Dadlani, G. H.; Miller, T. L.; Lipshultz, S. E. Cardiotoxicity of cancer chemotherapy: Implications for children. Paediatr. Drugs 7:187-202; 2005.
2. Simbre, V. C.; Adams, M. J.; Deshpande, S. S. Cardiomyopathy caused by antineoplastic therapies. Curr. Treat. Options Cardiovas. Med. 3:493-505; 2001.
3. Mertens, A.; Yasui, Y.; Neglia, J. P.; Potter, J. D.; Nesbit, M. E.; Ruccione, K.; Smithson, W. A.; Robison, L. L. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivors Study. J. Clin. Oncol. 19:3163-3172; 2001.
4. Singal, P. K.; Iliskovic, N. Doxorubicin-induced cardiomyopthy. N. Engl. J. Med. 339:900-905; 1998.
5. Giantris, A.; Abdurrahman, L.; Hinkle, A.; Asselin, B.; Lipshultz, S. E. Anthracycline-induced cardiotoxicity in children and young adults. Crit. Rev. Oncol. Hematol. 27:53-68; 1998.
6. Bleyer, W. A. The impact of childhood cancer in the United States and the world. Cancer J. Clin. 40:354-367; 1990.
7. Weiss, R. B. The anthracyclines: Will we ever find a better doxorubicine? Semin. Oncol. 19:670-686; 1992.
8. Wilson, K. S. Anthracyclines in early breast cancer. N. Engl. J. Med. 355:845; 2006.
9. Childs, A. C.; Phaneuf, S. L.; Dirks, A. J.; Phillips, T.; Leeuwenburgh, C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res. 62:4592-4598; 2002.
10. Herman, E. H.; Ferrans, V. J. Pathophysiology of anthracyclines cardiotoxicity. In: Bricker, J. T.; Green, D. M.; D'Angio, G. J., eds. Cardiac toxicity after treatment for childhood cancer. New York: Wiley-Liss; 1993:25-34.
11. Elliott, P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin. Oncol. 33:S2-S7; 2006.
12. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56:185-229; 2004.
13. Kim, Y.; Ma, A. G.; Kitta, K.; Fitch, S. N.; Ikeda, T.; Ihara, Y.; Simon, A. R.; Evans, T.; Suzuki, Y. J. Anthracycline-induced suppression of GATA-4 transcription factor: Implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 63:368-377; 2003.
14. Arai, M.; Yoguchi, A.; Takizawa, T. Mechanisms of doxorubicin-induced inhibition of sarcoplasmic reticulum CaATPase gene transcription. Mol. Med. 86:8-14; 2000.
15. Tolba, K.; Deliargyris, E. N. Cardiotoxicity of cancer therapy. Cancer Invest. 17:408-422; 1999.
16. Parker, M. A.; King, V.; Howard, K. P. Nuclear magnetic resonance study of doxorubicin binding to cardiolipin containing magnetically oriented phospholipid bilayers. Biochim. Biophys. Acta 1514:206-216; 2001.
17. Caulfield, J. B.; Bittner, V. Cardiac matrix alterations induced by adriamycin. Am. J. Pathol. 133:298-230; 1988.
18. Mladosievicova, B.; Foltinova, A.; Luptak, I.; Petrasova, H.; Hulin, I. Frequency-domain analysis of the QRS complex after treatment of childhood cancer with anthracycline cytostatics. Pediatr. Cardiol. 22:478-482; 2001.
19. Wolf, M. B.; Baynes, J. W. The anticancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim. Biophys. Acta 1760:267-271; 2006.
20. Johnson, S. A. Anthracycline-induced cardiotoxicity in adult hematologic malignancies. Semin. Oncol. 33:S22-S27; 2006.
21. Scully, R. E.; Lipshultz, S. E. Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc. Toxicol. 7:122-128; 2007.
22. Benvenuto, G. M.; Ometto, R.; Fontanelli, A.; Fortunate, A.; Ruffini, P. A.; Fosser, V.; Morandi, P. Chemotherapy-related cardiotoxicity: New diagnostic and preventive strategies. Ital. Heart J. 4:655-667; 2003.
23. Dolci, A.; Dominici, R.; Cardinale, D.; Sandri, M. T.; Panteghini, M. Biochemical markers for predicting chemotherapy induced cardiotoxicity: Systematic review of the literature and recommendations for use. J. Ital. Cardiol. 7:604-611; 2006.
24. Adamcova, M.; Sterba, M.; Simunek, T.; Potacova, A.; Popelova, O.; Mazurova, Y.; Gersl, V. Troponin as a marker of myocardial damage in drug-induced cardiotoxicity. Expert Opin. Drug. Saf. 4:457-472; 2005.
25. Stein, B. C.; Levin, R. I. Natriuretic peptides: Physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am. Heart. J. 135:914-923; 1998.
26. Bettencourt, P. M. Clinical usefulness of B-type natriuretic peptide measurement: Present and future perspectives. Heart 91:1489-1494; 2005.
27. Levin, E. R.; Gardner, D. G.; Samson, W. K. Natriuretic peptides. N. Engl. J. Med. 339:321-328; 1998.
28. Vanderheyde, M.; Bartunek, J.; Goethals, M. Brain and other natriuretic peptides: Molecular aspects. Eur. J. Heart Fail. 6:261-268; 2004.
29. Bonow, R. O. New insight into the cardiac natriuretic peptides. Circulation 93:1946-1950; 1996.
30. Mair, J. Role of cardiac natriuretic peptide testing in heart failure. Clin. Chem. 48:977-978; 2002.
31. Clerico, A.; Zucchelli, G. C.; Pilo, A.; Passino, C.; Emdin, M. Clinical relevance of biological variation: The lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. Clin. Chem. Lab. Med. 44:366-378; 2006.
32. Jourdain, P.; Jondeau, G.; Funck, F.; Gueffet, P.; Le Helloco, A.; Donal, E.; Aupetit, J. F.; Aumont, M. C.; Galinier, M.; Eicher, J. C.; Cohen-Solal, A.; Juillière, Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49:1733-1739; 2007.
33. O'Neill, J. O.; Bott-Silverman, C. E.; McRae, 3rd, A. T.; Troughton, R. W.; Ng, K.; Starling, R. C.; Young, J. B. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am. Heart J. 149:363-369; 2005
34. Daugaard, G.; Lassen, U.; Bie, P.; Pedersen, E. B.; Jensen, K. T.; Abildgaard, U.; Hesse, B.; Kjaer, A. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur. J. Heart Fail. 7:87-93; 2005.
35. Bauch, M.; Ester, A.; Kimura, B.; Victorica, B. E.; Kedar, A.; Phillips, M. I. Atrial natriuretic peptide as a marker for doxorubicin induced cardiotoxic effects. Cancer 69:1492-1497; 1992.
36. Tikanoja, T.; Riikonen, P.; Perkkio, M.; Helenius, T. Serum N-terminal atrial natriuretic peptide (NTANP) in the cardiac follow-up in children with cancer. Med. Pediatr. Oncol. 31:73-78; 1998.
37. Poutanen, T.; Tikanoja, T.; Riikonen, P.; Silvast, A.; Perkkio, M. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J. Clin. Oncol. 21:2349-2356; 2003.
38. Hayakawa, H.; Komada, Y.; Hirayama, M.; Hori, H.; Ito, M.; Sakurai, M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med. Pediatr. Oncol. 37:4-9; 2001.
39. Soker, M.; Kervancioglu, M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med. J. 26:1197-1202; 2005.
40. Lipshultz, S. E.; Hinkle, A. S.; French, C. A.; Kozlowski, A. M.; Constine, L. S. Accelerated atherosclerosis contributes to elevated global risk for premature symptomatic cardiovascular disease in survivors of childhood cancer. Abstract No: 3203, ASCO Annual Meeting; 2003.
41. Germanakis, I.; Kalmanti, M.; Parthenakis, F.; Nikitovic, D.; Stiakaki, E.; Patrianakos, A.; Vardas, P. E. Correlation of plasma N-terminal probrain natriuretic peptide levels with left ventricle mass in children treated with anthracyclines. Int. J. Cardiol. 108:212-215; 2006.
42. Nousiainen, T.; Jantunen, E.; Vanninen, E.; Remes, J.; Puustinen, J.; Rantala, A.; Vuolteenaho, O.; Hartikainen, J. Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients. Eur. J. Haematol. 61:347-353; 1998.
43. Nousiainen, T.; Jantunen, E.; Vanninen, E.; Remes, J.; Vuolteenaho, O.; Hartikainen, J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur. J. Haematol. 62:135-141; 1999.
44. Nousiainen, T.; Vanninen, E.; Jantunen, E.; Remes, J.; Ritanen, E.; Vuolteenaho, O.; Hartikainen, J. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin. Sci. (Lond.) 101:601-607; 2001.
45. Nousiainen, T.; Vanninen, E.; Jantunen, E.; Puustinen, J.; Remes, J.; Rantala, A.; Vuolteenaho, O.; Hartikainen, J. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J. Intern. Med. 251:228-234; 2002.
46. Okumura, H.; Iuchi, K.; Yoshida, T.; Nakamura, S.; Takeshima, M.; Takamatsu, H.; Ikeno, A.; Usuda, K.; Ishikawa, T.; Ohtake, S.; Matsuda, T. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol. 104:158-163; 2000.
47. Suzuki, T.; Hayashi, D.; Yamazaki, T.; Mizuno, T.; Kanda, Y.; Komuro, I.; Kurabayashi, M.; Yamaoki, K.; Mitani, K.; Hirai, H.; Nagai, R.; Yazaki, Y. Elevated B-type natriuretic peptide levels after anthracycline administration. Am. Heart J. 136:362-363; 1998.
48. Sandri, M. T.; Salvatici, M.; Cardinale, D.; Zorzino, L.; Passerini, R.; Lentati, P.; Leon, M.; Civelli, M.; Martinelli, G.; Cipolla, C. M. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction? Clin. Chem. 51:1405-1410; 2005.
49. Elbl, L.; Vasova, I.; Navratil, M.; Vorlicek, J.; Malaskova, L.; Spinar, J. Comparison of plasmatic levels of B-natriuretic peptide with echocardiographicindicators of left ventricle function after doxorubicin therapy. Vnitr. Lek. 52:563-570; 2006.
50. Neri, B.; De Scalzi, M.; De Leonardis, V.; Gemelli, M. T.; Ghezzi, P.; Pacini, P. Preliminary study on behaviour of atrial natriuretic factor in anthracycline-related cardiac toxicity. Int. J. Clin. Pharmacol. Res. 11:75-81; 1991.
51. Meinardi, M. T.; van Veldhuisen, D. J.; Gietema, J. A.; Dolsma, W. V.; Boomsma, F.; van den Berg, M. P.; Volkers, C.; Haaksma, J.; de Vries, E. G.; Sleijfer, D. T.; van der Graaf, W. T. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. 19:2746-2753; 2001.
52. Perik, P. J.; De Vries, E. G.; Boomsma, F.; van der Graaf, W. T.; Sleijfer, D. T.; van Veldhuisen, D. J.; Gietema, J. A. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors. Anticancer Res. 25:3651-3657; 2005.
53. Pichon, M. F.; Cvitkovic, F.; Hacene, K.; van der Graaf, W. T.; Sleijfer, D. T.; van Veldhuisen, D. J.; Gietema, J. A. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo 19:567-576; 2005.
54. Wu, A. H. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: The role of biologic variation in the interpretation of results. Am. Heart J. 152:828-834; 2006.
55. Bruins, S.; Fokkema, M. R.; Romer, J. W.; Dejongste, M. J.; van der Dijs, F. P.; van den Ouweland, J. M.; Muskiet, F. A. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin. Chem. 50:2052-2058; 2004.